Viatris Inc.

NASDAQ:VTRS

Drug Manufacturers - Specialty & Generic

Healthcare
$20.28 -2.29%

-$0.36 today

Market cap
$23.25B
Beta
0.90
P/E (TTM)
-59.9
EPS (TTM)
-$0.26
Dividend yield
3.12%
52W Low $8.63High $17.53

Volume 13.21M

Average 10.58M

VTRS Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Viatris Inc.NASDAQ: VTRS

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization dips below year-ago levels

Q2 FY2026 depreciation & amortization of $672.3M fell 0.9% year over year, behind the +1.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 0.6% from the prior quarter. Over 3 fiscal years it compounded at -2.6% a year.

Context

  • Depreciation & amortization amounted to 19.6% of revenue in FY2025, up 1.2 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -0.9% toward the trailing-twelve-month pace of +1.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$672.3M-0.6% QoQ
Last fiscal yearDec 2025
$2.8B+3.3% YoY
LTMJun 2026
$2.8B+1.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.9%——
1 year+3.3%——
3-year CAGR-2.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
2.8B USD
Year-over-year change
+3.3%
4-year CAGR
-11.2%

Depreciation & Amortization vs competitors

How VTRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1.6% is the 6th highest of 10, against a peer median of +8.7%.
  • Depreciation & amortization amounts to 19.0% of revenue for VTRS, versus a peer median of 6.2%.
VTRS Competitors
Depreciation & Amortization for VTRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹21.51B INR+12.7%+19.7%6.5%
VTRSViatris Inc.LTM Jun 2026$2.8B USD+1.6%-2.6%19.0%
BHCBausch Health Companies Inc.LTM Jun 2026$1.17B USD-5.6%-4.7%10.8%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$989M USD-3.3%-8.5%5.7%
HLNHaleon plcFY2025£352.11M GBP+8.7%+7.1%3.2%
OGNOrganon & Co.LTM Sep 2026$344M USD+0.6%+19.4%5.6%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$194.29M USD-20.8%-2.4%6.2%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$89.45M USD+17.8%+15.3%9.7%
ALKSAlkermes plcLTM Sep 2026$80.71M USD+167.6%-29.6%4.6%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$57.48M USD+44.0%+30.0%8.0%
Peer median (excluding VTRS) —+8.7%+7.1%6.2%

Competitors are the stored peer set for VTRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(1.27B)2.08B54.7M(634.2M)(3.51B)
Depreciation & Amortization4.51B3.03B2.74B2.71B2.8B
Deferred Income Tax675.7M(25.9M)(387.1M)(767.6M)(476.5M)
Stock-Based Compensation111.2M116.4M180.7M146.1M177.7M
Change in Working Capital(1.8B)(922.6M)(711.3M)(318.6M)(2.5B)
Accounts Receivables59.3M(240.3M)78.6M300.1M334.6M
Inventory(427.6M)(259.5M)(613.3M)(723.4M)(106.4M)
Accounts Payables(70.4M)170.2M314.7M36M(168M)
Other Working Capital(1.37B)(593M)(491.3M)68.7M(2.56B)
Other Non-Cash Items797.4M(1.28B)922.1M1.17B5.84B
Operating Cash Flow3.02B3B2.8B2.3B2.32B
Capital Expenditures(509.4M)(489.4M)(474.5M)(326M)(378.8M)
Acquisitions (Net)277M0(667.7M)(350M)0
Purchases of Investments(30.2M)(30.2M)(26.3M)(26M)(23.9M)
Sales of Investments29.8M29.9M26.3M26M23.9M
Other Investing Activities115M1.96B280.6M2.48B(48.9M)
Investing Cash Flow(117.8M)1.47B(764.1M)1.8B(427.7M)
Debt Repayment(2.1B)(3.28B)(1.25B)(3.71B)100K
Common Stock Issued03.3M3.1M2.5M2.6M
Common Stock Repurchased(17.4M)0(250M)(250M)(500.5M)
Dividends Paid(399M)(581.6M)(575.6M)(574.8M)(561.2M)
Other Financing Activities(496.5M)(19.5M)(229.8M)205.6M(234.9M)
Financing Cash Flow(3.01B)(3.88B)(2.3B)(4.33B)(1.29B)
Effect of Forex Changes(30.9M)(38.9M)(2.5M)(30.7M)17.6M
Net Change in Cash(143.8M)556.3M(268.9M)(257.5M)611.9M
Free Cash Flow2.51B2.51B2.33B1.98B1.94B

Viatris Inc.

NASDAQ:VTRS

Intrinsic Alpha fair value

Locked

Current Price

$20.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.